Targeting PD-L1 in non-small cell lung cancer using CAR T cells
Abstract Antibodies against programmed cell death protein 1 (PD-1) and its ligand (PD-L1) have dramatically changed the landscape of therapies for non-small cell lung carcinoma (NSCLC); however, the majority of patients do not respond to these agents. In addition, hyperprogressive disease (HPD) deve...
Sparad:
| Huvudupphovsmän: | , , , , , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | engelska |
| Publicerad: |
2020
|
| Länkar: | https://doi.org/10.1038/s41389-020-00257-z https://www.nature.com/articles/s41389-020-00257-z.pdf |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Lägg till första kommentaren!